cyrilzakka/clinical-trials huggingface dataset:
Effects of Decompression in Patient With Acute vs Chronic Lumbar Radiculopathy

The study will be done to evaluate the effectiveness of Lumbar Spinal Decompression in patients with acute vs chronic lumbar radiculopathy. Study design will be Randomized control trial and sample size will be 30. Duration of study was of 6 month, convenient sampling was done. Data will be collected from DHQ Daska were randomly allocated in three groups via lottery method, baseline assessment was done. Patients of both gender (male and female) from 18 to 50 years with lumbar radiculopathy diagnosed through X-ray and physical examination will be included. Patients with systemic soft tissue and bony diseases will be excluded. Intervention duration of 4 weeks, 3 sessions in a week. Decompression of lumbar spine will be given once in a week. Whole procedure of treatment program will given to patients and written informed consent will be taken. Basic tools will be Visual analog scale (VAS), SLR, ODI, Inclinometer. Data was analyzed by using SPSS version 21

Low back pain (LBP) is one of the most common musculoskeletal conditions treated by physical therapists. Although lumbar traction is frequently used by physical therapists in the treatment of patients with LBP. We will use Manual Lumber Spinal Traction on patients with acute vs chronic lumber radiculopathy. The current study will determine the effect of decompression in relieving pain, increase range of motion and improving function in patients of acute and chronic lumbar radiculopathy. Lumbar traction (LT) is routinely used on its own or in conjunction with other treatments for the management of lumbar sciatica. We will use Manual lumbar traction along with hot pack, tens, mobilization and exercise therapy. Intervention duration of 4 weeks, 3 sessions in a week. Decompression of lumbar spine will be given once in a week.

Eligibility Criteria:
Inclusion Criteria:

* history of radicular pain with straight leg raise (SLR).
* Patients in the acute phase of (up to 6 weeks) included in group A
* Patients in chronic phase of (more than 6 weeks) included in group B

Exclusion Criteria:

* Any systemic soft tissue and bony disease.
* Patient with spinal tuberculosis, spinal fractures, pregnancy, cancer.
* Any recent surgery.
* Patient with any cervical or thoracic problem.
* Patients with any other serious pathology/red flags
Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma .

Role of ADC value and DWI in abbreviated MRI compared to post-contrast CT in follow-up of HCC after TACE.

Hepatocellular carcinoma (HCC) is the 5th most common cancer in the world and the most common in Egypt .

Trans-arterial chemoembolization (TACE) is the treatment recommended for unresectable HCC according to Barcelona clinic liver cancer staging and is widely used .

HCC is nourished only by the hepatic artery, so TACE causes ischemia and coagulative necrosis. However; viable neoplastic tissue residual may be seen after TACE. Assessment of post-TACE tumor response is important in determining treatment success and in guiding future therapy .

Many studies have assessed the diagnostic performance of multiphasic contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) in diagnosis of HCC with noted higher sensitivity of MRI compared to CT. CT or MRI are recommended for assessment of response after treatment as well .

Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) are functional MRI techniques that detect signal changes in tissues due to water proton motion. The intact membranes of viable tumor cells restrict water diffusion, whereas necrotic tumor cells with disrupted cell membranes exhibit increased water diffusion and which differentiate the biological activity of HCC

Eligibility Criteria:
Inclusion Criteria:

* Patients who underwent TACE for unresectable HCC with patent portal vein based on Doppler, no ascites, and satisfactory liver function.

Age between 20-year old and 85-year old

Exclusion Criteria:

* Estimated GFR less than 60 Previous history of severe allergic reaction to the iodinated contrast agent Patients with claustrophobia who can't undergo MR examination. Patients having cochlear implants or cardiac pacemaker
A Trimodal Prehabilitation Study for Patients Undergoing Major Abdominal Surgery

Prehabilitation programmes have the potential to reduce post-operative complications following abdominal cancer surgery by improving pre-operative fitness levels. Home-based prehabilitation programmes may be more cost effective than hospital-based programmes, but have issues with low compliance. The aims of our study are to assess whether mobile technologies such as smart watches and smartphone applications improve compliance with home-based prehabilitation programmes and to assess the effects of prehabilitation on pre-operative fitness levels in patients due to undergo major abdominal cancer surgery.

30 patients due to undergo major abdominal cancer surgery at The Christie NHS Foundation Trust will be enrolled to a pilot randomised controlled trial. They will randomised to either a home-based trimodal prehabilitation programme, delivered by the use of FitBit Smart Watches and Smartphone applications, or a control group who will receive a FitBit for physical activity monitoring only, for a period of 2-6 weeks prior to surgery. The prehabilitation programme will include exercise, nutritional, and psychological components. Study outcomes will include 6MWT (6-minute walk test), HADS (hospital anxiety and depression score), steps per day, length of stay post-operatively, and post-operative complications.

Eligibility Criteria:
Inclusion Criteria:

* be aged 18 years or over
* be able to consent to participate in the prehabilitation programme
* be undergoing major abdominal cancer surgery (including, but not limited to, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy)
* have at least 2 weeks to their operation date
* be able to understand written and spoken English

Exclusion Criteria:

* patients have any health conditions which will prevent them from safely taking part in a home-based exercise programme. For example, but not limited to, patients who have recently (within the past 3 months) had a myocardial infarction or a stroke or patients who have end-stage renal disease but are not on dialysis. We will use the "Safety Reference Guide to support exercise services in people with cancer" in The Lancet published paper "Exercise as part of routine cancer care"(5) to aid the screening of patients suitability.
* they have any bone metastasis
* are already active users of a FitBit device
Virtual Reality Software to Reduce Stress in Cancer Patients

The purpose of this study is to test the ability of virtual reality-based social support to increase patient adherence to radiation therapy by reducing patient distress.

This study will involve patients who have been diagnosed with breast or head and neck cancer and are suitable to receive radiation therapy. It is a single arm pilot trial designed to provide information on the safety, feasibility, and impacts of incorporating virtual reality (VR) software into the treatment plan of patients receiving radiation therapy with the goal of increasing patient adherence to radiation therapy.

Patients will be provided with VR-based education sessions prior to and during the course of radiation therapy. Patients' emotional and social distress levels will be assessed with questionnaires to measure the impacts of the VR software. Patients will be in the study for up to 3 months during regular cancer care, but the total time for the study procedures is anticipated to be 2-4 hours in total. Results from this study will be for research only and will not impact treatment decisions.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18 years old
2. Must be able to read and speak English
3. Diagnosis of breast or head and neck cancer
4. Treatment plan includes radiotherapy within the next 2 months
5. Signed study-specific informed consent prior to study entry

Exclusion Criteria:

1. Previous radiation therapy treatment
2. Neurologic deficits
3. Visual disorder
4. Neuro-psychiatric disorder
5. Use of neuro-psychiatric drugs
Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease

The overall objective is to evaluate the effectiveness of a school-centered primary and secondary prevention program on the prevalence of latent rheumatic heart disease among schoolchildren in Nepal, and to investigate the role of socioeconomic and environmental factors in the development and progression of rheumatic heart disease.

Three in four children worldwide grow up in regions of the world where patterns of acute rheumatic fever and rheumatic heart disease are endemic and where rheumatic heart disease accounts for \>300'000 deaths every year. Evidence from a systematic review and meta-analysis of 10 studies indicated an incidence of group A β-hemolytic streptococcal (GAHBS) pharyngitis among children in low- to upper-middle income countries of 10.8 per 100 child-years with considerable heterogeneity between individual reports.

Timely detection of GAHBS pharyngitis by use of rapid antigen detection tests and initiation of antibiotic treatment represents an effective target for primary prevention. Early stages of rheumatic heart disease manifest with morphologic or functional valvular changes that can only be detected with echocardiography and are therefore latent. Latent stages of rheumatic heart disease are reversible with timely initiation of secondary antibiotic prophylaxis. A school-centered approach provides an opportunity to provide equitable access to a primary and secondary prophylaxis program with the potential to substantially reduce the burden of rheumatic heart disease in endemic regions.

All children 5-16 years of age from Tulsi Secondary Boarding School in Tulsipur, Nepal, will be eligible for inclusion. Sociodemographic characteristics and will be collected by means of a standardized interview. In a study using an interrupted time series design, prevalence of latent rheumatic heart disease will be measured by means of transthoracic echocardiography before, and two and four years after implementation of a dedicated school nurse program providing health care through assessment, intervention and follow-up of GAHBS pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.

Investigators expect to find a decrease in prevalence of rheumatic heart disease after implementation of a dedicated school-centered prevention program primarily led by school nurses, and to identify sociodemographic and environmental factors associated with the development and progression of rheumatic heart disease.

Eligibility Criteria:
Inclusion Criteria:

* Age 5-16 years
* Attending Tulsi Secondary Boarding School in Tulsipur, Nepal.

Exclusion Criteria:

* Children / primary caregivers not providing informed consent to participate
* Children not attending Tulsi Secondary Boarding School in Tulsipur.
Brain and Cognitive Reserve

Ischemic strokes are one of the leading causes of handicap and death in elderly people in France.

Cognitive reserve (CR) is an active model, defined as a function of lifetime intellectual activities and other environmental factors that explain differential susceptibility to functional impairment in the presence of pathology or other neurological insult. CR is estimated using variables for cognitive activity: years of education, professional status, socioeconomic status... Furthermore, brain reverse (BR) is a passive and quantitative model that depend on brain size and other quantitative aspects of the brain that explain differential susceptibility to functional impairment in the presence of pathology.

Firstly, volume and localization of ischemic strokes have a great impact on CR and BR due to brain injury. On the other hand, CR influences the severity and the expression of cognitive diseases.

The investigators realize a prospective study in order to assess the impact of CR and BR on cognitive prognosis after a right middle cerebral artery ischemic stroke in elderly patients.


Eligibility Criteria:
Inclusion Criteria:

* ≥70 years old
* right middle cerebral artery ischemic stroke
* hospitalized in neurovascular unit of Pierre Wertheimer hospital between January 2015 to January 2016

Exclusion Criteria:

* Contraindication for MRI
* Hemorrhagic stroke
* Aphasia
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and to evaluate the safety and tolerability of a switch to DOR/ISL compared with continued BIC/FTC/TAF, through Week 48. The primary hypotheses are that (1) DOR/ISL is non-inferior to continued BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48, with a margin of 4 percentage points used to define non-inferiority; and (2) DOR/ISL is superior to BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48.


Eligibility Criteria:
The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

* Is HIV-1 positive with plasma HIV-1 RNA \<50 copies/mL
* Has been receiving BIC/FTC/TAF therapy with documented viral suppression (HIV-1 RNA \<50 copies/mL) for ≥3 consecutive months prior to providing documented informed consent and has no history of prior virologic treatment failure on any past or current regimen
* Female is not a participant of childbearing potential (POCBP); or if a participant of childbearing potential, not pregnant or breastfeeding, and is willing to use an acceptable contraceptive method or abstain from heterosexual intercourse for study duration

Exclusion Criteria:

* Has HIV-2 infection
* Has a diagnosis of an active acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within 30 days prior to screening
* Has active hepatitis B virus (HBV) infection
* Has chronic hepatitis C virus (HCV) infection with laboratory values consistent with cirrhosis
* Has a history of malignancy ≤5 years prior to providing documented informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
* Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or strong and moderate cytochrome P450 3A (CYP3A ) inducers
* Has a documented or known virologic resistance to DOR
* Has taken long-acting HIV therapy at any time (e.g., cabotegravir, lenacapavir)
* Is currently participating in or has participated in a clinical study and received (or is receiving) an investigational compound or device from 45 days prior to Day 1 through the study treatment period except those currently enrolled in the comparator arm of an ongoing DOR/ISL study
For a Better Interpretation of Quality of Life Scores of Kidney Transplant Patients: Determination of the Minimum Significant Change RetransQol

The project team developped and validated a French patient-based health-related quality of life instrument in kidney transplant: the QoL Retrans.

The aim of the study is to determine the minimum significant change of the valdiated tool: ReTransQol


Eligibility Criteria:
Inclusion Criteria:

* Patient with a transplant kidney

Exclusion Criteria:

* Patient not able to answer survey
Sorafenib for Imatinib/Sunitinib-failed GIST

With discovery of KIT (CD117) mutations and the advent of KIT tyrosine kinase inhibitor imatinib, there has been substantial improvement in overall survival in patients with advanced and/or metastatic gastrointestinal tumors (GIST). Recently, sunitinib showed activity as second-line therapy in GIST patients after failure with imatinib. However, virtually all patients will eventually progress or become intolerable after imatinib and sunitinib. In preclinical models, sorafenib inhibits KIT activity and cell growth of imatinib-resistant tumors. The objective of this multi-center, non-randomized phase II study is to evaluate the safety and activity of sorafenib given as third-line therapy for GIST.

This is a non-randomized, open-label, multi-center, phase II study recruiting patients with advanced GIST who are pretreated with both imatinib and sunitinib. The current study will provide an estimate of the activity and safety of sorafenib in GIST. The primary study endpoint is the disease control rate (DCR), defined as complete or partial response or stable disease of at least 24 weeks of sorafenib therapy. Secondary endpoints include PFS, OS and safety.

Patients with advanced (unresectable and/or metastatic) GIST who failed after previous therapy involving both imatinib and sunitinib will be eligible. Failure to imatinib and sunitinib is defined as disease progression regardless of intervening response during therapy, or intolerance. There is no limit to the number of prior therapies a patient may have received (e.g., patients may have received therapy with nilotinib, other TKIs, or chemotherapy in addition to imatinib or sunitinib).

Eligibility Criteria:
Inclusion Criteria:

* age over 18 years
* advanced GIST
* failed (progressed and/or intolerable) after prior treatments for GIST
* ECOG performance status of 0\~2
* resolution of all toxic effects of prior treatments
* no prior radiotherapy within 1 month before registration
* measurable lesion as defined by RECIST
* adequate marrow, hepatic, renal and cardiac functions
* provision of a signed written informed consent

Exclusion Criteria:

* severe co-morbid illness and/or active infections
* pregnant or lactating women
* history of other malignancies
* active CNS disease not controllable with radiotherapy or corticosteroids
* active and uncontrollable bleeding from gastrointestinal tract
* prior history of sorafenib use
* gastrointestinal obstruction or malabsorption syndrome
Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus (DM) within the study duration of 24 weeks.


Eligibility Criteria:
Inclusion criteria:

1. Filipino of Asian race
2. Patient using Linagliptin within label or locally approved indication. The prescription of Linagliptin to the patient must be in the course of normal clinical practice and independent of the decision to include the patient in the study.
3. Male or female patients more than 18 years old
4. Body mass index less than or equal to 40
5. Diagnosed with type 2 DM
6. Uncontrolled type 2 DM with fasting blood sugar of more than 126 mg/dl and/or HbA1c more than 7%.

Exclusion criteria:

1. Diagnosed with type 1 DM
2. Patients with acute illness requiring hospitalization in the past one month
3. Patients participating in a different study that includes an investigational drug
4. Patients with known hypersensitivity reaction to Linagliptin or any of tis components
5. Pregnant women and those women who have intentions of getting pregnant within the study duration
6. Nursing women
7. Patients with concomitant conditions that contraindicates Linagliptin use as described in its product information
Investigation of the Aural Symptoms and Dizziness in Patients With Temporomandibular Joint Disorders

120 male and female patients aged between 18-65 years who apply to the outpatient clinic and diagnosed with TMD will be included in the study. Patients will be divided into 3 groups as Muscle Disorders (Group 1), Temporomandibular Joint Disorders (Group 2) and degenerative joint diseas (osteoarthrosis) (Group 3) according to DC/TMD axis I diagnostic criteria.

maximum mouth opening, TMJ sound, pain levels, tinnitus, and dizziness are evaluated.

120 male and female patients aged between 18-65 years who apply to the outpatient clinic and diagnosed with TMD will be included in the study. Patients will be divided into 3 groups as Muscle Disorders (Group 1), Temporomandibular Joint Disorders (Group 2) and degenerative joint diseas (osteoarthrosis) (Group 3) according to DC/TMD axis I diagnostic criteria.

Demographic data of all patients participating in the study will be obtained. Then, physical examination will reveal maximum mouth opening, right and left lateral movement, deflexion, deviation. Accompanying tinnitus, ear fullness and dizziness will be questioned.

All measurements, including maximum mouth opening, and physical examination will be performed with patients sitting upright in an anatomical position in a chair. All measurements will be performed by the same physical therapist with 7 years of experience in TMD.

In the measurement of maximum mouth opening, patients will be asked to open their mouths as wide as possible. The distance between the anterior incisors is measured with the help of a ruler suitable for millimeter measurement. Maximum mouth opening distance is a physical examination method frequently used to determine the motion and function of the jaw joint. Functional mouth opening is accepted as 35-40 mm (12).

For the evaluation of TMJ sound, the TMJ is palpated with the thumb and middle fingers and the sound heard when opening and closing the mesh is noted.

Pain levels are measured using a 10-point visual analog scale (VAS). The presence of bruxism is determined on physical examination based on the presence of abnormal tooth wear, tooth marks in the buccal region, tooth marks on the tongue, and hypertrophy of the masseter muscle.

The sense of fullness in the ear, tinnitus, and dizzyness, which the patients reported themselves, is questioned. The relationship between having TMD, clinical characteristics and dizziness will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* being 18-65 years of age
* diagnosed with TMD

Exclusion Criteria:

* Lack of cognitive ability to understand test instructions, illliteracy, aphasia, presence of a known psychiatric illness
* Patients under the age of 18 and over the age of 65
* Having another systemic disease that will cause TMD (cancer, rheumatological diseases)
* Presence of disease that will increase a anotherural symptoms or cause d d (presence of disease of vertigo, history of vertigo)
* Presence of a history of cervical pain, cervical spondylosis, cervical disc herniation
Post-placental Intrauterine Device Insertion During Cesarean Section

Effective, reversible postpartum contraception decreases the chance of rapid repeat pregnancy and poor perinatal outcome in a subsequent pregnancy especially in women delivered by cesarean section.The traditional 6-week postpartum visits not evidenced based and may not meet patient needs, particularly with respect to provision of contraception.Intrauterine device placement after delivery of the placenta is an appealing strategy for increasing access to postpartum Intrauterine device because it does not require a separate postpartum visit.

Advantage of post-placental Intrauterine device insertion, Intrauterine devices are recommended as first-line contraceptives by the American Academy of Pediatricians. The Centers for Disease Control and Prevention united state . Medical Eligibility Criteria for Contraceptive Use places no restrictions on use, and states advantages generally outweigh the risks for immediate postpartum use of Intrauterine devices.


Eligibility Criteria:
Inclusion Criteria:

1. Age group : 18-40 years
2. Women who will be willing to undergo elective cesarean section
3. women desire using Copper IUD as long acting contraceptive method.

Exclusion Criteria:

1. Intrauterine infection.
2. Fundal Myoma.
3. Hemorrhagic disorder
4. Genital tract malignancy
5. Uterine atony
6. Sexually transmitted infection.